FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2782896696> ?p ?o ?g. }

• W2782896696 endingPage "256" @default.
• W2782896696 startingPage "249" @default.
• W2782896696 abstract "In the neoadjuvant setting, blockade of HER2 plus use of an aromatase inhibitor in patients with HER2-positive and oestrogen receptor (ER)-positive breast cancer leads to a pathological complete response in 21% of patients. Convergence of HER2 and ER signals on RB1 suggests that a combined pharmacological intervention directed to these targets could be synergistic. To test this approach, we combined palbociclib to block RB1, fulvestrant to block ER, and trastuzumab with pertuzumab to block HER2 in patients with HER2-positive, ER-positive breast cancer.NA-PHER2 is a multicohort, open-label, exploratory, phase 2 study done at seven sites in Italy. Patients were eligible for the first cohort if they had previously untreated, histologically confirmed, unilateral, invasive, HER2-positive, ER-positive breast cancer and were suitable for neoadjuvant therapy. Patients were treated every 3 weeks with intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) and intravenous pertuzumab (840 mg loading dose in the first cycle and then at 420 mg) for six cycles plus oral palbociclib (125 mg once a day for 21 days in a 4-week cycle) and intramuscular fulvestrant (500 mg) every 4 weeks for five cycles. The coprimary endpoints were change from baseline in Ki67 expression at 2 weeks of treatment and at surgery (16 weeks after treatment) and changes in apoptosis from baseline to surgery. Secondary endpoints were clinical objective response (according to modified Response Evaluation Criteria in Solid Tumors) and pathological complete response. All patients who met eligibility criteria were assessed for the primary and secondary endpoints. All patients who received at least one cycle of therapy were assessed for safety. This trial is registered with ClinicalTrials.gov, number NCT02530424. The trial is ongoing and two further cohorts are being enrolled.Between May 20, 2015, and Feb 8, 2016, we enrolled 36 patients, of whom one was deemed ineligible for the study and five were found to be HER2-negative on retrospective analysis. Thus, 35 patients were included in safety analyses and 30 were assessed for the primary and secondary endpoints. At baseline, geometric mean Ki67 expression was 31·9 (SD 15·7), versus 4·3 (15·0) at week 2 (n=25; p<0·0001) and 12·1 (20·0) at time of surgery (n=22; p=0·013). The geometric mean for apoptosis was 1·2 (SD 0·3) at baseline versus 0·4 (0·4; p=0·019) at surgery. A clinical objective response immediately before surgery was achieved by 29 (97%; 95% CI 83-100) of 30 patients. At surgery, eight (27%; 95% CI 12-46) patients had a pathological complete response in breast and axillary nodes. The most frequent grade 3 adverse events were neutropenia (ten [29%]), diarrhoea (five [14%]), and stomatitis, increased alanine aminotransferase, and hypersensitivity reactions (one [3%] of each event). No grade 4 or serious adverse events were recorded in the study and there were no deaths.The combination of palbociclib, fulvestrant, trastuzumab, and pertuzumab had a significant effect on the expression of Ki67 at 2 weeks and at surgery. Triple targeting of ER, HER2, and RB1 in HER2-positive and ER-positive breast cancer could be an effective chemotherapy-free treatment strategy. Further clinical testing and additional molecular characterisation is necessary, not only in hormone receptor-positive tumours but also in tumours without HER2 amplification.Pfizer and Roche." @default.
• W2782896696 created "2018-01-26" @default.
• W2782896696 creator A5018118709 @default.
• W2782896696 creator A5029732013 @default.
• W2782896696 creator A5037733792 @default.
• W2782896696 creator A5041398398 @default.
• W2782896696 creator A5048969389 @default.
• W2782896696 creator A5053376791 @default.
• W2782896696 creator A5061761089 @default.
• W2782896696 creator A5068497911 @default.
• W2782896696 creator A5074479074 @default.
• W2782896696 creator A5088697304 @default.
• W2782896696 creator A5088908049 @default.
• W2782896696 date "2018-02-01" @default.
• W2782896696 modified "2023-10-18" @default.
• W2782896696 title "Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study" @default.
• W2782896696 cites W2075894019 @default.
• W2782896696 cites W2097698108 @default.
• W2782896696 cites W2107311126 @default.
• W2782896696 cites W2111578514 @default.
• W2782896696 cites W2114445859 @default.
• W2782896696 cites W2123591186 @default.
• W2782896696 cites W2130594114 @default.
• W2782896696 cites W2140055441 @default.
• W2782896696 cites W2146308386 @default.
• W2782896696 cites W2146383973 @default.
• W2782896696 cites W2147299492 @default.
• W2782896696 cites W2148345265 @default.
• W2782896696 cites W2150134401 @default.
• W2782896696 cites W2151134970 @default.
• W2782896696 cites W2151262170 @default.
• W2782896696 cites W2162982444 @default.
• W2782896696 cites W2167188058 @default.
• W2782896696 cites W2290950904 @default.
• W2782896696 cites W2299045691 @default.
• W2782896696 cites W2461625475 @default.
• W2782896696 cites W2464376480 @default.
• W2782896696 cites W2528767298 @default.
• W2782896696 cites W2560406314 @default.
• W2782896696 cites W2592406193 @default.
• W2782896696 cites W2620993107 @default.
• W2782896696 doi "https://doi.org/10.1016/s1470-2045(18)30001-9" @default.
• W2782896696 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29326029" @default.
• W2782896696 hasPublicationYear "2018" @default.
• W2782896696 type Work @default.
• W2782896696 sameAs 2782896696 @default.
• W2782896696 citedByCount "115" @default.
• W2782896696 countsByYear W27828966962018 @default.
• W2782896696 countsByYear W27828966962019 @default.
• W2782896696 countsByYear W27828966962020 @default.
• W2782896696 countsByYear W27828966962021 @default.
• W2782896696 countsByYear W27828966962022 @default.
• W2782896696 countsByYear W27828966962023 @default.
• W2782896696 crossrefType "journal-article" @default.
• W2782896696 hasAuthorship W2782896696A5018118709 @default.
• W2782896696 hasAuthorship W2782896696A5029732013 @default.
• W2782896696 hasAuthorship W2782896696A5037733792 @default.
• W2782896696 hasAuthorship W2782896696A5041398398 @default.
• W2782896696 hasAuthorship W2782896696A5048969389 @default.
• W2782896696 hasAuthorship W2782896696A5053376791 @default.
• W2782896696 hasAuthorship W2782896696A5061761089 @default.
• W2782896696 hasAuthorship W2782896696A5068497911 @default.
• W2782896696 hasAuthorship W2782896696A5074479074 @default.
• W2782896696 hasAuthorship W2782896696A5088697304 @default.
• W2782896696 hasAuthorship W2782896696A5088908049 @default.
• W2782896696 hasConcept C121608353 @default.
• W2782896696 hasConcept C126322002 @default.
• W2782896696 hasConcept C143998085 @default.
• W2782896696 hasConcept C203092338 @default.
• W2782896696 hasConcept C2775930923 @default.
• W2782896696 hasConcept C2778292576 @default.
• W2782896696 hasConcept C2779744173 @default.
• W2782896696 hasConcept C2779786085 @default.
• W2782896696 hasConcept C2780482068 @default.
• W2782896696 hasConcept C2781164504 @default.
• W2782896696 hasConcept C530470458 @default.
• W2782896696 hasConcept C535046627 @default.
• W2782896696 hasConcept C71924100 @default.
• W2782896696 hasConcept C84606932 @default.
• W2782896696 hasConceptScore W2782896696C121608353 @default.
• W2782896696 hasConceptScore W2782896696C126322002 @default.
• W2782896696 hasConceptScore W2782896696C143998085 @default.
• W2782896696 hasConceptScore W2782896696C203092338 @default.
• W2782896696 hasConceptScore W2782896696C2775930923 @default.
• W2782896696 hasConceptScore W2782896696C2778292576 @default.
• W2782896696 hasConceptScore W2782896696C2779744173 @default.
• W2782896696 hasConceptScore W2782896696C2779786085 @default.
• W2782896696 hasConceptScore W2782896696C2780482068 @default.
• W2782896696 hasConceptScore W2782896696C2781164504 @default.
• W2782896696 hasConceptScore W2782896696C530470458 @default.
• W2782896696 hasConceptScore W2782896696C535046627 @default.
• W2782896696 hasConceptScore W2782896696C71924100 @default.
• W2782896696 hasConceptScore W2782896696C84606932 @default.
• W2782896696 hasIssue "2" @default.
• W2782896696 hasLocation W27828966961 @default.
• W2782896696 hasLocation W27828966962 @default.
• W2782896696 hasOpenAccess W2782896696 @default.
• W2782896696 hasPrimaryLocation W27828966961 @default.

• next